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Objective: To report a case of hypogonadotropic hypogonadism due to the chronic abuse of anabolic steroids
purchased over the Internet.
Design: Case report.
Setting: Endocrinology unit of the University of Brescia.
Patient(s): A 34-year-old man.
Intervention(s): A single dose (100 mg) of triptorelin (triptorelin test).
Main Outcome Measure(s): Clinical symptoms, androgen normalization, levels of serum testosterone, follicle-
stimulating hormone, and luteinizing hormone.
Result(s): Within 1 month, the patient’s serum testosterone was in the normal range, and he reported a return to
normal energy and libido.
Conclusion(s): The World Anti-Doping Code has proved to be a very powerful and effective tool in the harmoni-
zation of antidoping efforts worldwide, but it is insufficient to combat this illegal phenomenon. To tackle the serious
side effects caused by doping we believe that it is necessary to increase monitoring and adopt severe sanctions,
particularly with regard to Internet sites. (Fertil Steril 2010;94:2331.e1–e3. 2010 by American Society for
Reproductive Medicine.)
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specific aim of improving performance, despite well-known adverse
effects on health (1). This practice has spread to the general popula-
tion, in particular to young adults, along with the exaggerated ideals
of body image portrayed by the mass media (2–4). Over the last few
years, Internet marketing may have played an important role in
increasing consumption of anabolic drugs such as anabolic
androgen steroids (AAS) and clomiphene citrate (5). We describe
the case of a young male with prolonged hypogonadotropic hypogo-
nadism due to ongoing consumption of various doping drugs
purchased over the Internet, where they are readily available.CASE REPORT
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an unremarkable personal medical history. He admitted to having
used doping drugs since he was 21 years old. More specifically, he
would perform cycles of intramuscular injections of nandrolone
(25 mg) and stanazol (25 mg) daily for 8 weeks, followed by mester-
olone (50 mg/day) for 15 days. Then he would then take clomiphene
citrate (50 mg/day) for 1 week, followed by an injection of human
chorionic gonadotropin (2,000 IU) three times in 1 week. He had re-
peated these cycles from 1995 to 2005. From 2005 to August 2008,
to his nandrolone and stanazol cycle he added an intramuscular
injection of boldenone (50 mg) daily for 3 weeks. He said he had
bought all the drugs on the Internet.
The patient was 175 cm tall and 80 kg, and he appeared very
muscular and toned. His blood pressure and pulse rate were normal.
Examination of his heart, lungs, and abdomen were likewise unre-
markable. The physical examination showed normal secondary
sexual characteristics, but the genital examination revealed bilat-
eral testicular atrophy (volume 2.9 mL and weak consistence).
Despite his testicular atrophy, the semen analysis revealed a normal
count (79  x106 spermatozoa/mlmL) and mild morphology de-
rangements (between 46% and 58%). The blood count and chemis-
try were normal, but his level of creatine kinase was 454 IU/L
(normal range: 20–170 IU/L), alanine aminotransferase 61 IU/L
(normal range: 5–50 IU/L), and aspartate aminotransferase 23
IU/L (normal range: 5–50 IU/L). The endocrinologic investigations
are reported in Table 1.Fertility and Sterility Vol. 94, No. 6, November 2010 2331.e1
ty for Reproductive Medicine, Published by Elsevier Inc.
FIGURE 1
Triptorelin test showing a normal response.
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TABLE 1
Serum hormone profile in a man with hypogonadotropic
hypogonadism due to the chronic abuse of anabolic
steroids.
Hormone
September
2008
February
2009
Normal
range
FSH (mIU/mL) 1 2 1.5–13.0
LH (mIU/mL) <0.5 2 1–8
HGH (ng/mL) <0.1 <0.1 <0.4
IGF (ng/mL) 241 — 109–307
TSH (mIU/L) 1.249 1.345 0.270–4.200
FT4 (pg/mL) 7.9 — 7–18
DHEAS (pg/mL) 2.2 — 0.80–5.60
E2 (pg/mL) <10 — 11–45
T (ng/mL) 0.3 1.7 2.7–10
PRL (ng/mL) 14.7 13.5 3.0–23
SHBG (nmol/L) 8 21 13–71
Note:DHEAS¼ dehydroepiandrosterone sulfate; E2¼ estradiol; FSH¼
follicle-stimulating hormone; fT4 ¼ free thyroxine; HGH ¼ human
growth hormone; IGF ¼ insulin-like growth factor; LH ¼ luteinizing
hormone; PRL ¼ prolactin; SHBG ¼ sex hormone-binding globulin;
T ¼ testosterone; TSH ¼ thyroid-stimulating hormone.
Pirola. Anabolic steroids online. Fertil Steril 2010.In February 2009, the patient continued to report loss of libido
and great tiredness. A second physical examination was performed.
His levels of alanine transferase and creatine kinase were all within
the normal range, but the endocrinologic investigations were still ab-
normal with the exception of sex hormone-binding globulin level
(see Table 1). Because the situation had persisted for months after
ASS withdrawal, we administered a single dose (100 mg) of triptor-
elin (triptorelin test), which showed a normal response (Fig. 1). Ten
days after the triptorelin test, the patient reported a great ameliora-
tion of energy, and his serum testosterone was 7.0 ng/mL. One
month later, his serum testosterone was within the normal range,
and he reported a return to normal libido and energy.
DISCUSSION
Despite the perception that doping is a modern phenomenon, there
are many examples of substance use by ancient civilizations, includ-
ing extracts derived from plants or animals. Historically, the use of
drugs in sports can be traced back to 776 B.C. One of the earliest re-
ports describes the use of a diet of dried figs to improve the perfor-
mance of Charmis, the Spartan winner of the stadium race at the
Olympic Games of 668 B.C. (6). Later, Roman gladiators also
used unspecified stimulants to overcome fatigue and injury (7).
Amphetamines, the first ‘‘effective’’ performance-enhancing drugs,
crossed over into sports in the early 1950s. These drugs, nicknamed
la bomba by Italian cyclists, minimize the uncomfortable sensations
of fatigue during exercise (8). Since then, many other substances
have been used to improve athletic performance.
Epidemiologic data on the use and abuse of doping drugs are
notoriously difficult to obtain because the drugs are illegal. Never-
theless, the use of these substances appears to have become wide-
spread, ranging from the domain of elite athletics to the general
community in many countries (5, 9–12). The popularity of doping
drugs seems to be due to the large diffusion of print media, sports
and bodybuilding magazines, advertisements, and television (5).
Our patient reported over a decade of chronic consumption of2331.e2 Pirola et al. Anabolic steroids onlinea cocktail of doping drugs, mainly androgens, which caused his
prolonged hypogonadotropic hypogonadism; all were purchased
on Internet sites.
The side effects of the use and abuse of high doses of anabolic ste-
roids have been well documented. After the first report, a fatal heat-
stroke in a cyclist in 1967 after abuse of amphetamines (8), many
other reports have described the side effects of doping drugs (13–
19). Because they derive from testosterone, anabolic steroids have
pronounced effects on the male pituitary gonadal axis, affecting
the regulation of production of serum luteinizing hormone (LH)
and follicle-stimulating hormone and inducing a state of hypogona-
dotropic hypogonadism characterized by decreased serum endoge-
nous testosterone production and impaired spermatogenesis, often
reversible with withdrawal of the drugs (19). Another consequence
of ASS abuse is the reduction of sex hormone-binding globulin,
which will continue long after ASS withdrawal (20).
Our patient showed no spermatogenesis dysfunction, even though
he had used anabolic steroids for over a decade. This could be ex-
plained by his periodic self-administered treatment with clomiphene
citrate and human chorionic gonadotropin between the cycles of ste-
roids. Clomiphene is a selective estrogen receptor modulator that
blocks the feedback inhibition of estradiol at the level of the hypo-
thalamus, thus increasing pituitary release of both LH and follicle-
stimulating hormone (5, 21). In addition, clomiphene decreases
the conversion of androgen substrate to estrogen by aromatase
inhibition (22). It is this ability to block estrogen that leads to its
postcycle use by bodybuilders to reduce the development of gyneco-
mastia after self-administration of androgen drugs. Clomiphene is
extensively used in the induction of ovulation (23), but it has also
been used to reverse hypogonadotropic hypogonadism in many con-
ditions like falciform anemia, uremia, and alcohol abuse, and it stim-
ulates gonadotropin secretion in patients with sulpiride-induced
hyperprolactinemia and gonadotropin suppression (24).
Moreover, clomiphene and LH (LH–RH) have been successfully
used to treat severe hypothalamic-pituitary dysfunction due to ana-
bolic steroid abuse. Van Breda et al. (17) reported that supraphysio-
logic doses of LH-RH restored normal pituitary–testicular axis
interplay, and Tan et al. (25) used prolonged clomiphene citrate
treatment to cure symptomatic hypogonadism in bodybuilders.
The cycles of pituitary stimuli with clomiphene and human
chorionic gonadotropin could also explain why our patient did not
exhibit the hypothalamic-pituitary dysfunction that had been clini-
cally evident previously.Vol. 94, No. 6, November 2010
The most important information relevant to the present case, in
our opinion, is the apparent ease with which one can purchase these
substances on the Internet. Indeed, very recently, Melnik (5) con-
demned the ‘‘role of the World Wide Web’’ in illegal drug marketing,
reporting more than 47,500 new steroid-related cases in 2006, for an
increase of 400% since their debut in 2002 (26). Many online body-
building stores also give information on the use and combination of
drugs, their dosages, and their side effects. We have personally pur-
chased stanazol, nandrolone, and other doping drugs online, con-
firming how easy it is to obtain these drugs over the Internet.
Even though it has been largely demonstrated that more than 50%
of illicit androgens are made available to the fitness community
by licensed health-care providers (5), in our opinion the InternetFertility and Sterilitymay have played an important role in the increasing consumption
of anabolic drugs, especially among young people. Population
studies have documented widespread androgen abuse among stu-
dents all over the world in places such as South Africa, the United
Kingdom, Scandinavia, and Australia (27, 28). Moreover, a recent
investigation of Polish adolescents revealed doping drugs abuse by
6.2% of young men and 2.9% of women (11).
Although the World Anti-Doping Code, adopted in 2003 and ef-
fective as of 2004, has proved to be a very powerful and effective
tool in the harmonization of antidoping efforts worldwide, it has
not been sufficient to tackle this illegal phenomenon. For this reason,
we believe that it is necessary to increase monitoring and adopt more
severe sanctions, particularly with regard to Internet sites.REFERENCES1. Lippi G, Banfi G, Franchini M, Guidi GC. New
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